EUVIMEDEUVIMED entdecken
Crossref

Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer

Jianya Cai, Minjie Zhong, Jianhua Xu, Hongwei Cheng, Shuangta Xu

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Jianya Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Quanzhou Medical College, Quanzhou, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Diterpenes. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Quanzhou City Science and Technology Program, National Key Clinical Specialty Discipline Construction Program of China, Fujian Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a specific type of breast cancer that exhibits poor prognosis and complex tumor heterogeneity. The unique immune tumor microenvironment reveals great potential of immunotherapy in TNBC. Triptolide, a potential regulator of immune-related signaling, has shown potent antitumor activity in TNBC. However, the molecular mechanism of triptolide in TNBC is still controversial. This study identified interferon-γ (IFN-γ) as a therapeutical target of triptolide based on the analysis of prognostic biomarkers in TNBC. IFN-γ is an important component of immunotherapy and contributes to antitumor immune activation. Triptolide was found to significantly reverse the IFN-γ-inducible programmed death-ligand 1 (PD-L1) in TNBC. The combined treatment of triptolide and IFN-γ in a hydrogel delivery system remarkably induced the cytotoxic CD8 + T lymphocytes activation, showing a synergistic effect on the potent tumor inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsDiterpenesHumansInterferon-gammaB7-H1 AntigenTumor MicroenvironmentEpoxy CompoundsPhenanthrenes

Stichwörter der Autor:innen

Antitumor immunityIFN-γPD-L1Triple-negative breast cancerTriptolide

Substanzen

Interferon-gammaAntineoplastic AgentsDiterpenesB7-H1 AntigentriptolideEpoxy CompoundsPhenanthrenes

Autor:innen und Institutionen

  • Department of Surgery, Quanzhou Medical College, Quanzhou, China.
  • Department of Surgery, The Second Clinical Medical College of Fujian Medical University, Quanzhou, China.
  • Center of molecular imaging translational medicine, School of public health, Xiamen University, Xiamen, China.
  • Department of Surgery, The Second Clinical Medical College of Fujian Medical University, Quanzhou, China. Electronic address: hongwei1026@hotmail.com.

Förderung

  • Quanzhou City Science and Technology Program
  • National Key Clinical Specialty Discipline Construction Program of China
  • Fujian Provincial Health Commission

Zitieren

APA

Cai, J., Zhong, M., Xu, J., Cheng, H., & Xu, S. (2023). Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110346

Vancouver

Cai J, Zhong M, Xu J, Cheng H, Xu S. Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110346

BibTeX
@article{Cai2023,
  author = {Cai, Jianya and Zhong, Minjie and Xu, Jianhua and Cheng, Hongwei and Xu, Shuangta},
  title = {Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110346}
}
Kostenlos starten →